DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacotherapies for diabetic retinopathy: present and future.

Author(s): Schwartz SG, Flynn HW Jr

Affiliation(s): Bascom Palmer Eye Institute, Retina Center at Naples, 311 9th Street North, Naples, FL 34102, USA. sschwartz2@med.miami.edu

Publication date & source: 2007, Exp Diabetes Res., 2007:52487.

Publication type: Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.

Page last updated: 2008-03-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017